Health and economic burden of antimicrobial-resistant infections in Australian hospitals: a population-based model

• DOI: 10.1017/ice.2019.2
• Publication Date: 2019-03-19T13:11:38Z
• Authors: Teresa M. Wozniak; Emily J. Bailey; Nicholas Graves
• Keywords: Enterococcus faecium

Abstract Objective: To estimate the additional health and economic burden of antimicrobial-resistant (AMR) infections in Australian hospitals. Methods: A simulation model based on existing evidence was developed to assess mortality costs healthcare-associated AMR Escherichia coli (E. coli), Klebsiella pneumoniae, Pseudomonas aeruginosa, Enterococcus faecium , Staphylococcus aureus . Setting: public Findings: hospitals spent an AUD$5.8 million (95% uncertainty interval [UI], $2.2–$11.2 million) per year treating ceftriaxone-resistant E.coli bloodstream (BSI), estimated AUD$5.5 UI, $339,633–$22.7 MRSA patients. There are no reliable estimates excess morbidity from sites other than blood particular for highly prevalent E. causing urinary tract (UTIs). Conclusion: The limited evidence-base impact resistant infection UTIs limits studies estimating overall AMR. Such data increasingly important urgently needed support local clinical practice as well national global efforts curb spread